- Home
- USEA vs COCP Comparison
USEA vs COCP Comparison
Compare USEA & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | COCP |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 15.3M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | USEA | COCP |
|---|---|---|
| Price | $2.03 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 129.6K | 38.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | N/A | ★ 8.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.86 |
| 52 Week High | $2.28 | $2.19 |
Technical Indicators
Market Signals| Indicator | USEA | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 58.56 |
| Support Level | $1.57 | $1.00 |
| Resistance Level | $2.25 | $1.11 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 28.95 | 76.91 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of five dry bulk vessels, comprising two Kamsarmax and three Panamax vessels with an aggregate cargo-carrying capacity of approximately 396,297 dwt.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).